EXEL vs. CRSP

In the year-to-date period, EXEL achieves a 29.25% return, which is significantly higher than CRSP's -7.80% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current EXEL Sharpe Ratio is 2.65, which is higher than the CRSP Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of EXEL and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither EXEL nor CRSP has paid dividends to shareholders.

The maximum EXEL drawdown since its inception was -97.38%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for EXEL and CRSP.

Exelixis, Inc. (EXEL) has a higher volatility of 21.93% compared to CRISPR Therapeutics AG (CRSP) at 19.35%. This indicates that EXEL's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Exelixis, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.